BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.042919
-0.030981 (-41.92%)
At close: Sep 8, 2026
BioXcel Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 0.74 | 0.64 | 2.27 | 1.38 | 0.38 | - |
Revenue Growth | -14.52% | -71.67% | 64.20% | 268.00% | - | - |
Cost of Revenue | 0.35 | 0.16 | 2.14 | 1.26 | 0.02 | - |
Gross Profit | 0.39 | 0.48 | 0.12 | 0.12 | 0.36 | - |
Selling, General & Admin | 23.57 | 20.49 | 34.49 | 83.41 | 68.76 | 54.59 |
Research & Development | 21.56 | 30.25 | 30.44 | 84.33 | 91.24 | 52.34 |
Operating Expenses | 45.13 | 50.75 | 64.93 | 167.74 | 160 | 106.94 |
Operating Income | -44.73 | -50.27 | -64.8 | -167.62 | -159.65 | -106.94 |
Interest Expense | -17.22 | -16.98 | -15.13 | -13.31 | -8.21 | -0.04 |
Interest & Investment Income | 0.9 | 1.07 | 2.6 | 5.65 | 2.53 | 0.04 |
Other Non Operating Income (Expenses) | -9.61 | -3.52 | 20.17 | 0.39 | -0.43 | - |
EBT Excluding Unusual Items | -70.67 | -69.7 | -57.16 | -174.89 | -165.76 | -106.93 |
Merger & Restructuring Charges | -0.19 | -0.19 | -2.44 | -4.16 | - | - |
Pretax Income | -70.86 | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 |
Net Income | -70.86 | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 |
Net Income to Common | -70.86 | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 12 | 3 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 23 | 12 | 3 | 2 | 2 | 2 |
Shares Change | 389.70% | 381.58% | 39.21% | 4.00% | 6.23% | 21.63% |
EPS (Basic) | -3.15 | -5.73 | -23.51 | -98.33 | -94.67 | -64.87 |
EPS (Diluted) | -3.15 | -5.73 | -23.51 | -98.33 | -94.67 | -64.87 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -50.9 | -57.62 | -72.03 | -155.03 | -135.48 | -82.6 |
Free Cash Flow Per Share | -2.26 | -4.72 | -28.41 | -85.13 | -77.38 | -50.11 |
Gross Margin | 53.10% | 74.45% | 5.43% | 8.70% | 94.67% | - |
Operating Margin | -6028.57% | -7829.75% | -2859.84% | -12146.30% | -42572.00% | - |
Profit Margin | -9549.86% | -10887.38% | -2630.14% | -12974.85% | -44201.87% | - |
Free Cash Flow Margin | -6860.38% | -8974.30% | -3178.60% | -11233.77% | -36128.00% | - |
EBITDA | -44.51 | -49.97 | -64.5 | -167.3 | -159.32 | -106.64 |
D&A For EBITDA | 0.23 | 0.3 | 0.31 | 0.32 | 0.33 | 0.3 |
EBIT | -44.73 | -50.27 | -64.8 | -167.62 | -159.65 | -106.94 |